Shenzhen Baiyin Biotechnology

PAM2L Biotechnologies (Shenzhen Baiyin Biotechnology) is an innovative biomaterials company driven by synthetic biology and artificial intelligence (BT-IT). Founded in 2021 by Dr. Chao Zhong from the Shenzhen Institute of Advanced Technology, Chinese Academy of Sciences, the company has established an end-to-end DBAP (Design-Biosynthesis-Application-Product) platform. PAM2L specializes in developing high-performance, green, and sustainable protein- and polysaccharide-based materials. Its core product pipeline includes recombinant mussel adhesive protein, Colamin (sodium colaminate), and recombinant type XVII collagen, which are widely applied in wound care, medical aesthetics, cosmetics, and nutrition. The company has successfully commercialized several products and secured over RMB 200 million in Series A funding from major strategic investors like L'Oréal and Walgreens Boots Alliance.